• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by BrainsWay Ltd.

    4/20/26 4:05:04 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care
    Get the next $BWAY alert in real time by email
    S-8 POS 1 fs8pos_041626.htm FORM S-8 POS

    As filed with the Securities and Exchange Commission on April 20, 2026

     

    Registration No. 333-230979

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-8

    REGISTRATION STATEMENT

     

    UNDER THE SECURITIES ACT OF 1933

     

     

     

    BrainsWay Ltd.

    (Exact name of registrant as specified in its charter)

     

     

     

    State of Israel   Not Applicable
    (State or other jurisdiction of   (I.R.S. Employer
    Incorporation or organization)   Identification No.)

     

     

    16 Hartum Street

    RAD Tower, 14th Floor

    Har HaHotzvim

    Jerusalem, 9777516, Israel

    (Address of Principal Executive Offices, including Zip Code)

     

     

     

    Brainsway Ltd. 2014 Share Incentive Plan

    (Full title of the plan)

     

     

     

    BrainsWay USA, Inc.

    95 Washington Street

    Suite 104-323

    Canton, MA 02021, USA

    (Name and address of agent for service)

     

     

     

    (844) 386-7001

    (Telephone number, including area code, of agent for service)

     

    Copies to:

     

    Rick A. Werner, Esq.

    Jayun Koo, Esq.

    Haynes and Boone, LLP

    30 Rockefeller Plaza

    26th Floor

    New York, New York 10112

    Tel: +1 212 659-7300

    Sarit Molcho, Adv.

    Odeya Brick-Zarsky, Adv.

    S. Friedman, Abramson & Co.

    Azrieli Town

    146 Menachem Begin Road

    Tel Aviv 6492103, Israel

    +972 (3) 693-1931

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large Accelerated Filer ☐   Accelerated Filer ☒
      Non-Accelerated Filer ☐   Smaller Reporting Company ☐
          Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    BrainsWay Ltd. (the “Registrant”), is filing this Post-Effective Amendment No. 1 to Form S-8 Registration Statement to deregister certain ordinary shares, par value NIS 0.04 per share (the “Ordinary Shares”), originally registered by the Registrant for offer or sale pursuant to the Registrant’s 2014 Share Incentive Plan (the “2014 Plan”). The Registrant has resolved not to grant any more options under the 2014 Plan, and that both the registered shares underlying options not yet granted, as well as the shares underlying options that are surrendered (except in the case of surrender for the exercise into shares) or which cease to be exercisable under the 2014 Plan, shall be transferred to the share pool reserved for issuance under the Registrant’s 2019 Share Incentive Plan (the “2019 Plan”). The total number of Ordinary Shares available for grant under the 2014 Plan and carried over to the 2019 Plan (the “Carryover Shares”), is 3,626,200.

     

    This Post-Effective Amendment No. 1 is being filed to remove the Carryover Shares from registration.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Jerusalem, the State of Israel on the 20th day of April, 2026.

     

     

      BrainsWay Ltd.
      (Registrant)
       
       
      By:   /s/ Hadar Levy                                  
      Hadar Levy
      Chief Executive Officer

     

     

    SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of BrainsWay Ltd., has signed this Post-Effective Amendment to the Registration Statement on Form S-8 on the 20th day of April, 2026.

     

      BrainsWay USA, Inc.
      Authorized U.S. Representative
       
       
      By:   /s/ Ido Marom                                  
      Name: Ido Marom
      Title: Chief Financial Officer

     

     

    Pursuant to Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment to the Registration Statement on Form S-8.

     

     

     

    Get the next $BWAY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BWAY

    DatePrice TargetRatingAnalyst
    11/16/2023Outperform → Mkt Perform
    Raymond James
    3/3/2022$15.00Buy
    Loop Capital
    11/29/2021$14.00 → $15.00Buy
    HC Wainwright & Co.
    8/12/2021$17.00 → $14.00Buy
    HC Wainwright & Co.
    7/19/2021$17.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BWAY
    SEC Filings

    View All

    SEC Form S-8 filed by BrainsWay Ltd.

    S-8 - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:06:32 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by BrainsWay Ltd.

    S-8 POS - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:05:04 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by BrainsWay Ltd.

    20-F - Brainsway Ltd. (0001505065) (Filer)

    4/20/26 4:01:32 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

    BURLINGTON, Mass. and JERUSALEM, April 15, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today highlighted the growing trend across the U.S. payer landscape of coverage policies that allow appropriately trained nurse practitioners to administer Transcranial Magnetic Stimulation (TMS) therapy. A growing number of commercial insurers, Medicare Administrative Contractors (MACs), and government payers now permit psychiatric mental health nurse practitioners (PMHNPs) to administer TMS therapy, including Deep TMS™, when practicing in accordance with app

    4/15/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Participate in the 25th Annual Needham Virtual Healthcare Conference

    BURLINGTON, Mass. and JERUSALEM, April 13, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference at 8:45 AM ET on Wednesday, April 15, 2026. Please contact your Needham & Co. representative to request a meeting at the conference. About BrainsWayBrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulati

    4/13/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

    BURLINGTON, Mass. and JERUSALEM, March 26, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. ("Neurolief"). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief's Proliv™Rx system, a milestone defined under the terms of BrainsWay's August 2025 strategic investment transaction with Neurolief. "Our strategic investments in Neurolief are part of our long-term mi

    3/26/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Brainsway downgraded by Raymond James

    Raymond James downgraded Brainsway from Outperform to Mkt Perform

    11/16/23 7:31:55 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Loop Capital initiated coverage on BrainsWay with a new price target

    Loop Capital initiated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00

    3/3/22 4:42:28 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on BrainsWay with a new price target

    HC Wainwright & Co. reiterated coverage of BrainsWay with a rating of Buy and set a new price target of $15.00 from $14.00 previously

    11/29/21 6:24:14 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Zangen Abraham

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Mitrany Rayten Michal Ety

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:45 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Zacut David

    3 - Brainsway Ltd. (0001505065) (Issuer)

    3/18/26 4:05:17 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:33:58 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by BrainsWay Ltd.

    SC 13G/A - Brainsway Ltd. (0001505065) (Subject)

    11/14/24 1:32:48 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by BrainsWay Ltd.

    SC 13D - Brainsway Ltd. (0001505065) (Subject)

    11/13/24 6:09:51 PM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    $BWAY
    Leadership Updates

    Live Leadership Updates

    View All

    MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

    MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (NASDAQ:HYFT), bio-native AI company today announces the appointment of industry veteran R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025. "Scott's extensive experience leading financial strategy for high-growth, publicly traded healthcare and technology companies makes him an ideal addition to our executive team," said Dr. Jennifer Bath, MindWalk CEO. "His proven ability to strengthen financial systems, execute disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we scale our Bio-Native AI platform globally." Mr. Areglado brings more

    10/21/25 8:28:00 AM ET
    $BWAY
    $HYFT
    $ICAD
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BrainsWay Appoints Richard A. Bermudes, M.D. as Chief Medical Officer

    BURLINGTON, Mass. and JERUSALEM, Aug. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer (CMO), effective September 1, 2024. Dr. Aron Tendler, M.D., who has served as CMO since 2015, will continue to serve as a collaborator on important strategic research projects. "We are excited to have Richard join our team to lead and shape BrainsWay's clinical strategy and product roadmap. His extensive experience with TMS and brain stimulation therapies as a practicing phys

    8/29/24 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    Murchinson Takes Action to Replace Board of Directors of Nano Dimension at Upcoming Annual General Meeting

    Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

    8/3/23 3:00:00 PM ET
    $BWAY
    $INSG
    $MCK
    Medical/Dental Instruments
    Health Care
    Telecommunications Equipment
    Telecommunications

    $BWAY
    Financials

    Live finance-specific insights

    View All

    BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

    Q4 Revenue Grew 27% Year-Over-Year to Record $14.5 Million Q4 Operating Income of $1.9 Million; Adjusted EBITDA Increased by 53% to $2.3 Million, Reflecting Significant Operating Leverage  Full Year 2025 Revenue Increased by Approximately 27% YoY to $52.2 Million, and Net Income Increased by Approximately 161% YoY to $7.6 Million Remaining Performance Obligations Increased 43% to Approximately $70 Million Issuing 2026 Guidance: Expecting Revenue of $66 - $68 million (27% - 30% Growth), Operating Income of 13% - 14%, and Adjusted EBITDA of $12 - $14 Million (86% - 100% Growth) Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, March 11, 2026 (GLOBE NEWSWIR

    3/11/26 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026

    BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, March 11, 2026Time:8:30 AM Eastern TimeUnited States:1-877-300-8521Internationa

    2/25/26 8:00:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care

    BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights

    Revenue increased 29% to $13.5 million in Q3 2025 as compared with Q3 2024 Operating income totaled $1.3 million and Adjusted EBITDA rose approximately 80% to $2.0 million in Q3 2025, as compared with Q3 2024 Remaining performance obligations increased to $65 million FDA cleared an accelerated protocol for Deep TMS treatment of patients with major depressive disorder (MDD) Raised midpoint of full-year 2025 Revenue and EBITDA guidance Conference call to be held today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatm

    11/11/25 7:30:00 AM ET
    $BWAY
    Medical/Dental Instruments
    Health Care